Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034268 | PMC |
http://dx.doi.org/10.4103/1673-5374.270420 | DOI Listing |
Neural Regen Res
June 2020
CHR d'Orléans, Service d'Oncologie Médicale, Orléans, France.
Ideggyogy Sz
March 2017
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Neurology Department, Bakırköy/İstanbul.
Posterior reversible encephalopathy syndrome (PRES) is a reversible clinical and neuroradiological syndrome which may appear at any age and characterized by headache, altered consciousness, seizures, and cortical blindness. The exact incidence is still unknown. The most commonly identified causes include hypertensive encephalopathy, eclampsia, and some cytotoxic drugs.
View Article and Find Full Text PDFBMC Cancer
October 2012
Department of Medical Oncology, University General Hospital of Alexandroupolis, Dragana, 68100, Alexandroupolis, Thrace, Greece.
Background: The reversible posterior leukoencephalopathy syndrome is a clinical/radiological syndrome characterized by headache, seizures, impaired vision, acute hypertension, and typical magnetic resonance imaging findings. There are several reports in the literature that depict its occurrence in cancer patients. The list of common anticancer and supportive care drugs that predispose to reversible posterior leukoencephalopathy syndrome is expanding and includes not only a large number of chemotherapeutic agents but also an increased number of new targeted drugs, particularly angiogenesis inhibitors such as bevacizumab,sorefenib and sunitinib.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!